Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

This study tests whether adding a redness-reducing eye drop (Brimonidine Tartrate 0.025%) to an existing glaucoma eye drop combination (netarsudil/latanoprost) can reduce the eye redness that the glaucoma drops cause, without affecting pressure control. **You may be eligible if...** - You are 18–65 years old - You have been diagnosed with open-angle glaucoma or elevated eye pressure (ocular hypertension) - You are currently using the combination eye drop (netarsudil/latanoprost) for at least 2–6 weeks - You have noticeable eye redness (grade 2 or higher on the Efron scale) - Your vision is 20/30 or better in the study eye **You may NOT be eligible if...** - You are not on the specific combination eye drop - You have other eye conditions that would affect the results - You are unable to self-administer eye drops or arrange for someone to help Talk to your doctor to see if this trial is right for you.